IVDR Rule 7: Why an Indicative Value Isn't an Assigned One

IVDR's seven classification rules under Annex VIII get summarized often and understood shallowly, and nowhere more so than Rule 7 — the residual rule for standalone quality-control materials. On 9 September 2026 the Medical Device Coordination Group published Revision 5 of MDCG 2020-16 specifically to resolve a distinction manufacturers kept getting wrong: an indicative value on a control's label is not the same thing as an assigned value, and which one you have decides whether Rule 7 applies at all.

Why Rule 7 is residual, not default

Annex VIII's seven rules are applied in order of relevance, not convenience, and a device takes the highest class any applicable rule produces. Rule 7 exists for a narrow category: standalone control materials with no quantitative or qualitative assigned value, intended only to verify that an existing laboratory procedure is still performing as expected. It is tempting to treat Rule 7 as the default home for anything labeled "control," the way Rule 6 functions as the residual rule for devices Rules 1–5 and 7 do not otherwise reach. Both are residual rules, not starting points — which means the burden runs the other way. A manufacturer has to show why the earlier, more specific rules do not apply, and for controls, that means examining exactly what the product's labeling claims before assuming Class B follows automatically.

The line MDCG just drew

The practical confusion Rev.5 addresses is specific: many standalone controls carry labeling that states an indicative concentration range, or simply that a given analyte is present, without committing to a precise value the laboratory is meant to reproduce. Manufacturers reading that language conservatively worried it might already function as an assigned value, pushing the product out of Rule 7's Class B and into a classification tied to whatever device the control nominally supports — a jump that, for a control touching a companion diagnostic or high-risk assay, could mean the difference between Class B and Class C. MDCG 2020-16 Rev.5 settles it the other way: an indicative range or presence statement is not an assigned value. The laboratory, not the manufacturer, sets its own routine target values against that indicative information, which is exactly the arrangement Rule 7 was written to cover.

• Assigned value. A specific quantitative or qualitative result the manufacturer states the control should produce — the number or outcome a lab is meant to match.
• Indicative value. A stated range, approximate concentration, or simple presence/absence claim that describes the material without committing to it as a pass criterion.
• Assay-kit validity controls. Controls bundled with a specific kit to validate that run's performance carry an assigned value by their nature and follow implementing rule 1.6, not Rule 7.
• IFU scope. Rule 7's Class B only holds if the IFU limits the control's stated purpose to monitoring laboratory procedure — not to replacing the mandatory controls built into the IVD itself.

The classification question was never really about the control. It was about what the manufacturer's own labeling committed the product to being. Why Rule 7 disputes are usually IFU disputes

Where manufacturers get caught

The gap Rev.5 closes rarely comes from a manufacturer deliberately misclassifying a product. It comes from labeling language written for a commercial or scientific audience — a precise-sounding concentration figure added to differentiate the control from a competitor's, or a confidence-building claim about analyte presence — that a Notified Body technical reviewer reads as a de facto assigned value. Because Rule 7's Class B self-certification route and implementing rule 1.6's device-linked classification sit on opposite sides of whether a Notified Body is involved at all for many controls, the IFU wording is not a drafting detail; it is the classification decision. Reviewing control and calibrator labeling against this specific test, before a Notified Body raises it as a technical-file finding, is a faster and cheaper place to resolve the question than during conformity assessment for a broader IVD regulatory strategy.

None of this changes the underlying rule, which has read the same way since IVDR took effect. What changed is that MDCG has now put a specific, citable answer behind a distinction manufacturers were making inconsistently on their own judgment. Control and calibrator manufacturers who treat their own IFU wording as the classification evidence it actually is — rather than a marketing detail disconnected from Annex VIII — are the ones who will not be revisiting a Rule 7 classification mid-review.